Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab

Rose Parisi, Emily A Cowen, Stephanie Gu, Melissa Pulitzer, Mark B. Geyer, Amber C. King, Alina Markova

Blood (2022) 140 (Supplement 1): 11583.

https://doi.org/10.1182/blood-2022-160312

Published: 2022

Journal Articles

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Kinga Hosszu, Brigitte Senechal, Jennifer A. Spross, Alexis Mark, Avinash Desai, Elizabeth R. Cathcart, M. Lia Palomba, Neeta Pandit-Taskar

Blood (2022) 140 (Supplement 1): 10341–10342.

https://doi.org/10.1182/blood-2022-167962

Published: 2022

Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Blood (2021) 138 (26): 2828–2837.

https://doi.org/10.1182/blood.2021013379

Published: 2021

Includes: Supplemental data

Journal Articles

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Elizabeth Halton, Peter Kane, Brigitte Senechal, Eileen M. Geoghegan, Vijay Reddy, Mark S. Berger, Dale Ludwig, Neeta Pandit-Taskar, Craig S. Sauter

Blood (2021) 138 (Supplement 1): 4810.

https://doi.org/10.1182/blood-2021-144994

Published: 2021

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139898

Published: 2020

Journal Articles

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Mark B. Geyer, MD, Amber C. King, PharmD, BCOP, Justin C. O'Brien, Jae H. Park, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-137016

Published: 2020

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F. Huntington, Matthew S. Davids, Jennifer R. Brown, Darko Antic, Ryan Jacobs, Inhye E. Ahn, Jeffrey Pu, Krista M. Isaac, Paul M. Barr, Chaitra S. Ujjani, Mark B. Geyer, Ellin Berman, Andrew D. Zelenetz, Nikita Malakhov, Richard R. Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme F. Perini, Shuo Ma, Christine E. Ryan, Adrian Wiestner, Craig A. Portell, Mazyar Shadman, Elise A. Chong, Danielle M. Brander, Suchitra Sundaram, Amanda N. Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew R. Wilson, Piers E. M. Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S. Skånland, Raul Cordoba, Toby A. Eyre

Blood (2020) 136 (10): 1134–1143.

https://doi.org/10.1182/blood.2020006965

Published: 2020

Includes: Supplemental data

Journal Articles

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

Chaitra S. Ujjani, MD, Lindsey E. Roeker, MD, Mazyar Shadman, MD MPH, Kate J Whitaker, BA, Allison P. Jacob, Mark B. Geyer, MD, Colleen Dorsey, BSN, RN, Andrew D. Zelenetz, MD PhD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 1758.

https://doi.org/10.1182/blood-2019-124002

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3888.

https://doi.org/10.1182/blood-2019-125165

Published: 2019

Journal Articles

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Ryan J. Daley, PharmD, Sridevi Rajeeve, MD, Charlene C. Kabel, PharmD, Jeremy J. Pappacena, PharmD, BCOP, Sarah E. Stump, PharmD, BCPS, BCOP, Jessica A. Lavery, MS, Martin S. Tallman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 3816.

https://doi.org/10.1182/blood-2019-124727

Published: 2019

Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 5079.

https://doi.org/10.1182/blood-2019-122745

Published: 2019

Journal Articles

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

Mark B. Geyer, Meier Hsu, Sean M. Devlin, Martin S. Tallman, Dan Douer, Jae H. Park

Blood (2017) 129 (13): 1878–1881.

https://doi.org/10.1182/blood-2016-11-749507

Published: 2017

Includes: Supplemental data

Journal Articles

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Jae H. Park, Mark B. Geyer, Renier J. Brentjens

Blood (2016) 127 (26): 3312–3320.

https://doi.org/10.1182/blood-2016-02-629063

Published: 2016

Journal Articles

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Monica Bhatia, MD, Mark B Geyer, AB, Courtney Baker, RN, MSN, PNP, Erin Morris, RN, BSN, Deirdre Duffy, BS, Diane George, MD, James H Garvin, Jr., MD, PhD, Prakash Satwani, MD, Joseph Schwartz, MD, Sandra Foley, CPNP, Ria Hawks, CPNP, Elana Hamburger-Smilow, CPNP, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 3504.

https://doi.org/10.1182/blood.V116.21.3504.3504

Published: 2010

Journal Articles

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Mark B Geyer, AB, Angela M Ricci, BA, Lauren Harrison, RN, MSN, Deirdre Duffy, BS, Monica Bhatia, MD, James H Garvin, Jr., MD, Diane George, MD, Prakash Satwani, MD, Alexandra C Cheerva, MD, MS, Julie Talano, MD, Fevzi Ozkaynak, MD, Theodore B. Moore, MD, MS, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 36.

https://doi.org/10.1182/blood.V116.21.36.36

Published: 2010

NARROW

Dermatologic Adverse Events in Acute Lymphocytic Leukemia Patients Treated with Bispecific T-Cell Engager Blinatumomab

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only